Trulicity ® (dulaglutid) injektion

För fullständig produktresumé för Trulicity® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Orsakar Trulicity® (dulaglutid) illamående och hur ska det behandlas?

Gastrointestinala biverkningar, inklusive illamående, var de vanligaste biverkningarna i kliniska studier med dulaglutid.

SE_cFAQ_GLP057_NAUSEA
SE_cFAQ_GLP057_NAUSEA
en-US

How should Nausea be treated in Patients ?

In clinical studies with dulaglutide, management of nausea consisted of symptomatic treatment such as antiemetics and antacids as per usual standards of care.1

When does Nausea occur and how long does it last?

In clinical pharmacology studies conducted in patients with Type 2 Diabetes mellitus, nausea was generally

  • reported during the first 2 to 3 days after the initial dose and
  • declined with subsequent doses.1,2

Gastrointestinal adverse events, including nausea were 

Onset of Nausea With Once-Weekly Dulaglutide Treatment in the AWARD-1, AWARD-5, and GBDN* Studies1

Abbreviation: AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes.

*Note: GBDN was an ambulatory blood pressure monitoring safety study. 

Did Nausea lead to Study Drug Discontinuation?

In phase 2 and 3 studies, the incidence of nausea leading to discontinuation was

  • 1.9% for dulaglutide 1.5 mg, and
  • 1.0% for dulaglutide 0.75 mg.1

How often was Nausea reported in the Clinical Trials?

In the pooled data derived from the 3 placebo-controlled trials of 26 weeks duration or longer, nausea was reported in

  • 21.1% of patients receiving dulaglutide 1.5 mg
  • 12.4% of patients receiving dulaglutide 0.75 mg, and
  • 5.3% of patients receiving placebo.3

Across 8 clinical studies, AWARD-1 through AWARD-8 ( Percent of Patients Experiencing Nausea in AWARD studies ), the percent of patients experiencing nausea ranged between

  • 10.5% to 28.0% for dulaglutide 1.5 mg, and
  • 6.6% to 18.0% for dulaglutide 0.75 mg.1,4
 Percent of Patients Experiencing Nausea in AWARD studies 4

Study 

Dulaglutide 1.5 mg 

Dulaglutide 0.75 mg 

AWARD-3 5– Comparator – Metformin (MET)

26 weeks

19.0%

10.7% 

AWARD-56– Comparator – Sitagliptin and Placebo
Background anti-diabetic medications: MET ≥ 1,500 mg/day

52 weeks

17.0%a

13.0%a

AWARD-67– Comparator – Liraglutide
Background anti-diabetic medications: MET ≥ 1,500 mg/day

26 weeks

20.0% 

N/A 

AWARD-88 – Comparator – Placebo
Background anti-diabetic medications: Glimepiride (GLIM)

24 weeks

10.5%b

N/A 

AWARD-19 – Comparator – Exenatide (twice daily) and Placebo
Background anti-diabetic medications: MET ≥ 1,500 mg/day and pioglitzaone 30-45 mg/day

26 weeks

28.0%b

16%bc

AWARD-210– Comparator – Insulin glargine (GLA)d
Background anti-diabetic medications: MET ≥ 1,500 mg/day and GLIM ≥ 4 mg/day

52 weeks

14.3%e

6.6%e

AWARD-911 – Comparator – Placebo
Background anti-diabetic medications: GLAd with or without  MET ≥ 1,500 mg/day

28 weeks

12.0%b

N/A 

AWARD-4 12– Comparator – Insulin glargined
Background anti-diabetic medications: MET ≥ 1,500 mg/day and Insulin lisprod

26 weeks

26.0%e

18.0%e

Abbreviations: AWARD = Assessment of Weekly AdministRation of LY2189265 in Diabetes; GLA = insulin glargine; GLIM = glimepiride; MET = Metformin; N/A = not applicable; 

asignificant vs sitagliptin.

bsignificant vs placebo.

csignificant vs exenatide.

dtitrated

esignificant vs glargine.

Nausea in the AWARD-11 Study

The AWARD-11 trial was a phase 3, randomized, double-blind, active-controlled, parallel-arm study that assessed the efficacy and safety of dulaglutide 3.0 mg and dulaglutide 4.5 mg compared to dulaglutide 1.5 mg in patients with inadequately controlled T2DM on concomitant metformin therapy.13

In the AWARD-11 study, through 52 weeks of treatment with dulaglutide, a total of 292 patients experienced nausea where 

  • 87 patients, 14.2%, were receiving 1.5 mg dulaglutide
  • 99 patients, 16.1%, were receiving 3 mg dulaglutide, and 
  • 106 patients, 17.3%, were receiving 4.5 mg dulaglutide.13-15

References

1Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2Martin S, Loghin C, Cui X, et al. The nausea profile of once weekly dulaglutide 1.5 mg. Poster presented at: American Association of Pharmaceutical Scientists Annual Meeting and Exposition: November 2-6, 2014. San Diego, CA. Poster W5273.

3Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

4Kugler AJ, Thiman ML. Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data. Diabetes Metab Syndr Obes. 2018;11:187-197. https://doi.org/10.2147/DMSO.S134960

5Umpierrez G, Povedano ST, Manghi FP, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37(8):2168-2176. https://doi.org/10.2337/dc13-2759

6Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37(8):2149-2158. http://dx.doi.org/10.2337/dc13-2761

7Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349-1357. https://doi.org/10.1016/S0140-6736(14)60976-4

8Dungan KM, Weitgasser R, Perez Manghi F, et al. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes Obes Metab. 2016;18(5):475-482. http://dx.doi.org/10.1111/dom.12634

9Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37(8):2159-2167. https://doi.org/10.2337/dc13-2760

10Giorgino F, Benroubi M, Sun JH, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38(12):2241-2249. https://doi.org/10.2337/dc14-1625

11Pozzilli P, Norwood P, Jódar E, et al. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab. 2017;19(7):1024-1031. http://dx.doi.org/10.1111/dom.12937

12Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet. 2015;385(9982):2057-2066. https://doi.org/10.1016/S0140-6736(15)60936-9

13Frias JP, Nevárez Ruiz L, Li YG, et al. Efficacy and safety of higher dulaglutide doses (3.0 mg and 4.5 mg) when added to metformin in patients with type 2 diabetes: a phase 3, randomized, double-blind, parallel arm study (AWARD-11). J Endocr Soc. 2020;4(suppl 1):A1036. Endocrine Society abstract OR26-08. https://doi.org/10.1210/jendso/bvaa046.2057

14Frias JP, Bonora E, Nevarez Ruiz LA, et al. Efficacy and safety of dulaglutide 3mg and 4.5mg vs. dulaglutide 1.5mg: 52-week results from AWARD-11. Diabetes. 2020;69(suppl 1). American Diabetes Association abstract 357-OR. https://doi.org/10.2337/db20-357-OR

15Frias JP, Bonora E, Ruiz LN, et al. Efficacy and safety of dulaglutide 3 mg and 4.5 mg vs dulaglutide 1.5 mg: 52-week results from AWARD-11. Oral presentation presented at: 80th Annual Meeting of the American Diabetes Association; June 12-16, 2020. Accessed September 15, 2020.

Datum fӧr senaste ӧversyn September 23, 2020


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Klicka för att chatta är offline

Skriv din fråga till oss